| Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults B Suh, S Park, DW Shin, JM Yun, B Keam, HK Yang, E Ahn, H Lee, ... Annals of oncology 25 (11), 2260-2266, 2014 | 132 | 2014 |
| A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who … S Park, MH Lee, M Seong, ST Kim, JH Kang, BC Cho, KH Lee, EK Cho, ... Annals of Oncology 31 (10), 1397-1404, 2020 | 129 | 2020 |
| Artificial intelligence–powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non–small-cell lung cancer S Park, CY Ock, H Kim, S Pereira, S Park, M Ma, S Choi, S Kim, S Shin, ... Journal of Clinical Oncology 40 (17), 1916-1928, 2022 | 127 | 2022 |
| High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers B Suh, S Park, DW Shin, JM Yun, HK Yang, SJ Yu, CI Shin, JS Kim, E Ahn, ... Hepatology 61 (4), 1261-1268, 2015 | 113 | 2015 |
| Characteristics and outcome of ROS1-positive non–small cell lung cancer patients in routine clinical practice S Park, BC Ahn, SW Lim, JM Sun, HR Kim, MH Hong, SH Lee, JS Ahn, ... Journal of Thoracic Oncology 13 (9), 1373-1382, 2018 | 89 | 2018 |
| Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status J Lee, Y La Choi, J Han, S Park, HA Jung, JM Su, SH Lee, JS Ahn, K Park, ... Journal of Thoracic Oncology 15 (11), 1758-1766, 2020 | 70 | 2020 |
| DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC S Park, H Lee, B Lee, SH Lee, JM Sun, WY Park, JS Ahn, MJ Ahn, K Park Journal of Thoracic Oncology 14 (9), 1640-1650, 2019 | 69 | 2019 |
| Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor S Park, S Ha, SH Lee, JC Paeng, B Keam, TM Kim, DW Kim, DS Heo PLoS One 13 (1), e0189766, 2018 | 59 | 2018 |
| High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell … S Park, S Olsen, BM Ku, MS Lee, HA Jung, JM Sun, SH Lee, JS Ahn, ... Cancer 127 (16), 3019-3028, 2021 | 46 | 2021 |
| Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma S Park, JH Shim, B Lee, I Cho, WY Park, Y Kim, SH Lee, Y La Choi, J Han, ... Lung Cancer 134, 7-15, 2019 | 42 | 2019 |
| Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations S Park, S Park, SH Lee, B Suh, B Keam, TM Kim, DW Kim, YW Kim, ... The Korean journal of internal medicine 31 (6), 1140, 2016 | 39 | 2016 |
| Changes in noninvasive liver fibrosis indices and spleen size during chemotherapy: potential markers for oxaliplatin-induced sinusoidal obstruction syndrome S Park, HY Kim, H Kim, JH Park, JH Kim, KH Kim, W Kim, IS Choi, YJ Jung, ... Medicine 95 (2), e2454, 2016 | 35 | 2016 |
| Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor … S Park, B Keam, SH Kim, KH Kim, YJ Kim, JS Kim, TM Kim, SH Lee, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2015 | 34 | 2015 |
| Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor S Park, J Han, JM Sun Lung Cancer 127, 66-68, 2019 | 33 | 2019 |
| Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma S Park, JG Joung, YW Min, JY Nam, D Ryu, D Oh, WY Park, SH Lee, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 32 | 2019 |
| Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB‐4 liver fibrosis index B Suh, JM Yun, S Park, DW Shin, TH Lee, HK Yang, E Ahn, H Lee, ... Cancer 121 (21), 3818-3825, 2015 | 31 | 2015 |
| Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non–Small-Cell Lung Cancer … S Park, TM Kim, JY Han, GW Lee, BY Shim, YG Lee, SW Kim, IH Kim, ... Journal of Clinical Oncology 42 (11), 1241-1251, 2024 | 30 | 2024 |
| Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma S Park, D Oh, YL Choi, SA Chi, K Kim, MJ Ahn, JM Sun Cancer 128 (11), 2148-2158, 2022 | 30 | 2022 |
| Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study S Park, JM Sun, YL Choi, D Oh, HK Kim, T Lee, SA Chi, SH Lee, YS Choi, ... ESMO open 7 (1), 100385, 2022 | 30 | 2022 |
| Biomarker‐driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum‐based chemotherapy S Park, J Shim, PGS Mortimer, SA Smith, RE Godin, SJ Hollingsworth, ... Cancer 126 (17), 4002-4012, 2020 | 29 | 2020 |
